Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

INTRODUCTION: Atopic dermatitis (AD) is a heterogeneous disease, with involvement of the T-helper cell (Th) 2, Th22, and potentially Th17 pathways, supporting the use of interleukin (IL)-23 and IL-22 blockade in AD. METHODS: This phase 2, multicenter, randomized, double-blind, placebo-controlled tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Tyring, Stephen K., Rich, Phoebe, Tada, Yayoi, Beeck, Stefan, Messina, Izabella, Liu, Jie, Huang, Xiaohong, Shumack, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805909/
https://www.ncbi.nlm.nih.gov/pubmed/36588137
http://dx.doi.org/10.1007/s13555-022-00876-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805909/
https://www.ncbi.nlm.nih.gov/pubmed/36588137
http://dx.doi.org/10.1007/s13555-022-00876-x

Ejemplares similares